1. Current trends in the acute treatment of ischemic stroke: analysis from the Paul Coverdell National Acute Stroke Program.
- Author
-
Asaithambi G, Tong X, Lakshminarayan K, Coleman King SM, and George MG
- Subjects
- Aged, Brain Ischemia epidemiology, Female, Fibrinolytic Agents administration & dosage, Humans, Infusions, Intra-Arterial standards, Infusions, Intravenous standards, Infusions, Intravenous trends, Injections, Intra-Arterial standards, Injections, Intravenous standards, Injections, Intravenous trends, Male, Middle Aged, Quality Improvement standards, Stroke epidemiology, Thrombolytic Therapy standards, Thrombolytic Therapy trends, Treatment Outcome, Brain Ischemia therapy, Infusions, Intra-Arterial trends, Injections, Intra-Arterial trends, Quality Improvement trends, Registries, Stroke therapy
- Abstract
Background: The intra-arterial treatment (IAT) of acute ischemic stroke (AIS) is now evidence-based and given the highest level of recommendation among eligible patients. Using a multi-state stroke registry, we studied the trend in IAT among patients with AIS over 11 years and its impact on the utilization of intravenous thrombolysis (IVT) within the same 11 years., Methods: Using data from the Paul Coverdell National Acute Stroke Program (PCNASP), we studied trends in IVT and IAT for patients with AIS between 2008 and 2018. Trends over time were examined for rates of IVT only, IAT only, or a combination of IVT and IAT (IVT+IAT). Favorable outcome was defined as discharge to home., Results: During the study period there were 595 677 patients (mean age 70.4 years, 50.4% women) from 646 participating hospitals with a clinical diagnosis of AIS in the PCNASP. Trends for IVT only, IAT only, and IVT+IAT all significantly increased over time (P<0.001). Total use of IVT and IAT increased from 7% in 2008 to 19.1% in 2018. The rate of patients discharged to home increased significantly over time among all treatment groups (P<0.001)., Conclusion: In our large registry-based analysis, we observed a significant increase in the use of IAT for the treatment of AIS, with continued increases in the use of IVT. Concurrently, the percent of patients with favorable outcomes continued to increase., Competing Interests: Competing interests: KL is a member of the adverse event committee for Abbott/St Jude Medical., (© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2020
- Full Text
- View/download PDF